2023 Medicine stocks which list
With China's aging population and three years of epidemic, we are increasingly concerned about the medical, and in the future medical in the residents of the consumption ratio, will also be higher and higher, today to give you a compilation of medicine stocks which list, you can pay attention to it.
What are the pharmaceutical stocks at a glance
1, Hengrui Medical 600276: Hengrui Medical Corporation is one of the largest research and production bases of anti-tumor drugs, surgical drugs and contrast agents. The company's products cover a wide range of areas such as antineoplastic drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and so on.
2, Myriad Medical 300760: Shenzhen Myriad Biomedical Electronics Co., Ltd. is mainly engaged in the research and development of medical devices, manufacturing, marketing and services, the main products cover three major areas, life information and support, in vitro diagnostics and medical imaging.
3, WuXi PharmaTech 603259: Wuxi WuXi PharmaTech New Drug Development Co., Ltd.'s main business is mainly for the discovery of small molecule chemical drugs, research and development and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide all kinds of new drug development, production and supporting services.
4, aier ophthalmology 300015: aier ophthalmology hospital group co., LTD is an ophthalmology medical institutions, the company is mainly engaged in all kinds of ophthalmic disease diagnosis and treatment, surgical services and medical optometry.
5, Pientzehuang 600436: Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a company mainly engaged in the production and sale of ingots, tablets, granules and other pharmaceutical products and tourism commodities. The main products of the company are Pientzehuang and its series of products.
6, Yunnan Baiyao 000538: Yunnan Baiyao Group Co., Ltd. is a company mainly engaged in chemical raw materials, chemical pharmaceutical preparations, proprietary Chinese medicines, Chinese herbal medicines and biological products.
China's stock market according to normal analysis, this year should be some performance, but the stock market "gray rhino" should also pay attention to the Russian-Ukrainian conflict broke out in a nuclear war, the Taiwan Straits war, the United States to strengthen China's economic embargo, the domestic economic recovery is less than expected.
What are the Pharmaceutical Stocks at a Glance
HealthCareSelectSectorSPDRETFHealthCareSelectSectorSPDRETF (XLV) has slipped 3.6% in 22 years, much better than the broader S&P 500, which has slipped 19.4%.
CNBCPro screens the ETF for stocks that have a "buy" rating from more than 55 percent of analysts and an average price target gain of at least 20 percent.
CVS (CVS) has a buy rating from 58% of analysts, and its average price target implies a 28% upside. The stock is down 9.7 percent over the last year -- a smaller drop than the broader market.
Earlier this week, CVS said its full-year EPS would likely hit the high end of its previous range, while revenue would beat previous estimates.
Dexcom (DXCM), a maker of glucose monitors, also issued positive guidance, noting that fourth-quarter revenue would beat the average estimate of analysts surveyed by FactSet.
Nearly three-fifths of analysts have a buy rating on the stock, and its average price target implies nearly 22% upside. Like CVS, Dexcom has outperformed the S&P 500, albeit by a small margin. The stock lost 15.6 percent of its market value last year.
Bio-Techne (TECH) was one of the hardest hit stocks on the '22 list, plunging 35.9%. But 2023 looks much better, with 70% of analysts tracking the stock rating it a buy, and the average analyst expecting the stock to rally nearly 28% over the next year.
Wells Fargo analyst Timothy Daley last week upgraded Bio-Techne to a hold rating from a hold, noting that "valuation has reset to reasonable levels while long-term growth prospects remain intact."
UnitedHealth's (UNH) fourth-quarter revenue and EPS topped analysts' average estimates through Friday, according to FactSet. The managed care and insurance company also reaffirmed its full-year 2023 EPS, revenue and cash flow forecasts.
About 75 percent of analysts tracking UnitedHealth rate it a buy, with an average price target implying 20 percent upside. unitedHealth is up 5.6 percent in '22.
Pharmaceutical Manufacturing Concept Stocks for 2023 are:
(1), River Chemical Corporation:
From the perspective of the compounded revenue growth in the last three years, the company's compounded revenue growth in the last three years is -33.36%, with the lowest revenue in the past three years being $139 million in '19, and the highest in '20 being $244 million.
The industry has been changed to pharmaceutical manufacturing.
Shares have risen 8.35% in the last five trading days, with a high of $5.67 and a total market capitalization of $172 million.
(2), Renhe Pharmaceuticals:
From the point of view of the last three years of revenue compound growth, the last three years of revenue compound growth of 3.8%, the past three years of revenue as low as 4.278 billion yuan in 20 years, the highest is 4.936 billion yuan in 21 years.
The company belongs to the pharmaceutical manufacturing industry, industry segmentation is a OTC products, health products, mainly production and sales enterprises.
Shares are up 2.43% in the last 5 days and 1.67% in 2023.
(3), YAHONG PHARMACEUTICAL:
In terms of compounded revenue growth in the last three years, the highest was $4,574.88 in 21 years.
In the last five trading days, Yahong Pharmaceuticals - U during the overall increase of 2.94%, the highest price of $ 16.98, the lowest price of $ 15.95, the total market capitalization rose by $ 279 million.
(4), Teyi Pharmaceuticals:
From the perspective of the last three years revenue compound growth, the last three years revenue compound growth of -9.28%, the past three years revenue as low as 633 million yuan in 20 years, the highest for the 19 years of 921 million yuan.
The company operates in the pharmaceutical manufacturing health care production medical devices, daily necessities wholesale technical services housing rental.
Shares have risen 7.91% in the last five trading days, topping out at $24.51, with a total market capitalization up $438 million.
(5), Nuocheng Jianhua:
From the point of view of the company's revenue compound growth in the last three years, the last three years of revenue compound growth of 7.64 million percent, the past three years, the lowest revenue of 1.247 million yuan in 19 years, the highest for the 21 years of 1.043 billion yuan.
Looking back over the last five trading days, Nocheng Jianhua-U has declined on five days. The overall decline during the period was 8.06%, with a high of $14.83 and a low of $14.32, for a total volume of 24,522,900 lots.